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Abstract
Objective—To identify neuromuscular, balance and vision factors that contribute to falls in
recently treated breast cancer survivors (BCS) and explore links between fall risk factors and
cancer treatment
Design—Case-control plus prospective observation
Setting—Comprehensive cancer center
Participants—BCS within two years chemotherapy completion and/or on adjuvant endocrine
therapy (N=59; mean age: 58 yrs)
Intervention—not applicable
Main outcome measures—Objective measures of postural control, vision and neuromuscular
function included 1) a sensory organization test (SOT), 2) a visual assessment battery, 3) muscle
mass by DXA, and 4) neuromuscular function with strength by repetition maximum, power by
timed stair climb, and gait speed by 4m walk. Falls were self-reported for the past year
(retrospective) and monthly for six months (prospective).
Results—58% of BCS reported falls in the past year. BCS with a history of falls had lower SOT
scores with a vestibular deficit pattern in postural control (p<.01) and took longer to read letters on
the contrast sensitivity chart (p<.05). Vestibular score on the SOT mediated the relationship
between treatment and falls among BCS who received chemotherapy only, but not adjuvant
endocrine therapy.
Conclusions—Results of this pilot project suggest that balance disturbances of vestibular origin
and delays in detecting low contrast visual stimuli are associated with falls in BCS. Future studies
that track falls and fall risk factors in BCS from diagnosis through treatment are warranted as are
studies that can identify treatment-related vestibular dysfunction and altered visual processing.
© 2010 The American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.
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Fractures are a particular concern for breast cancer survivors (BCS)1, 2 because of the
combined effect of chemotherapy and adjuvant endocrine therapy on fracture risk factors,
including bone mass2 and fall risk3. Even though falls may play an important role in fracture
etiology4, there are few studies of falls in BCS. We reported that BCS with chemotherapy-
induced amenorrhea fall more than their age-matched, cancer-free peers5 and Chen et al
(2005) reported an increased falls in BCS using data from the Women’s Health Initiative
cohort3.
In older adults, leading risk factors for falls include a prior history of falls, muscle weakness,
gait and/or balance impairment and poor vision6–8. Cancer treatment may increase fall risk
because treatment can worsen traditional risk factors, potentiate less common risk factors or
contribute to falls in new ways. Breast cancer chemotherapy may cause peripheral
neuropathy9 and weakness10. Adjuvant endocrine therapy has unknown effects on
neuromuscular function and may alter vision in several ways11–15. Despite study limitations
that included examination of few fall risk factors and use of simple balance and strength
assessments, prior work suggests that both balance and strength are worse in estrogen-
deficient BCS compared to controls and that falls are more common in BCS with muscle
weakness5.
The purpose of this study was to compare BCS with and without a recent history of falls on
a comprehensive battery of objective tests of fall risk factors. The objectives of this study
were to: 1) identify balance, neuromuscular and visual factors associated with past history of
falls in BCS, 2) determine if factors that discriminate past fallers from non-fallers can
predict future falls and 3) examine whether balance, neuromuscular and visual factors are
potential mediators of the relationship between the type of cancer treatment and falls.
METHODS
Sample and Setting
Women were recruited through state and hospital cancer registries, clinician referral, and
community events. To best evaluate persistent treatment effects rather than acute side effects
of cancer chemotherapy that might be linked to falls, eligibility criteria included a diagnosis
of non-metastatic breast cancer (stages 0–IIIa), completion of chemotherapy within the past
two years with or without adjuvant hormone therapy OR within two years of surgery and
presently taking a selective estrogen receptor modulator (SERM) or aromatase inhibitor (AI)
that was initiated ≥ 6 months earlier, postmenopausal, and <70 years of age (to separate
treatment effects from aging). Women were excluded if they had cognitive difficulties or
medical conditions that, in the opinion of the study investigator (KWS), affected testing
protocols. A convenience sample of N=60 was chosen for this preliminary study, balancing
available resources, while retaining power for regression models. The Institutional Review
Board approved the study.
Procedures
Women who responded to invitation letters from the cancer registry, advertisements, or
oncologist referral were contacted by telephone and screened for eligibility. Eligible women
who agreed to participate provided written informed consent, completed questionnaires and
underwent balance, neuromuscular and vision testing. Tests were performed by the same
technician except for the SOT that was administered by one of two trained physical
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therapists. All tests followed standard operating procedures that included moderate verbal
encouragement. Participants also completed mailed or emailed monthly fall reports for the
next six months. Late reports (>2 weeks) were followed up by phone and information
obtained verbally.
Measures
Demographic and clinical characteristics including breast cancer stage, treatment type,
diagnosis and treatment dates were obtained by self-report.
Falls were assessed retrospectively through self-report of falls in the previous year and
prospectively for six months by monthly reports. A fall was defined as unintentionally
coming to rest on the ground or at some other lower level, not as a result of a major intrinsic
event or overwhelming hazard16. A past fall was only counted if it occurred within the past
year and after cancer diagnosis. To reduce reporting bias, we used a standard definition of a
fall, gave identical instructions for tracking falls to all participants regardless of fall history,
and confirmed affirmative fall reports by telephone.
Balance problems consistent with neuropathy, vestibular loss, and CNS disorders that
contribute to fall risk17 were assessed by computerized dynamic posturography (CDP)a. We
conducted the sensory organization test (SOT) that systematically removes or alters useful
visual and somatosensory input across six sensory conditions (Fig 1) and provides
equilibrium scores for each condition based on center of gravity sway. Sensory analysis
ratios are calculated to identify the degree to which a person can use information from the
somatosensory (SOM), visual (VIS) and vestibular (VEST) sensory systems to maintain
balance, by comparing conditions 2 to 1, 4 to 1 and 5 to 1, respectively. The preference ratio
(PREF) determines reliance on visual information to maintain balance even when the visual
information is incorrect from sway-referencing the visual surround (Conditions 3 vs 6 and 2
vs 5).
Gait speed (m/s) was evaluated by timing the participant as she walked in a straight line for
4m at both normal and fast walking speeds on an electronic gait matb. Slow gait speed is
associated with increased fall risk6.
Neuromuscular function was evaluated by the following tests: 1) Maximal lower body
strength by a one-repetition maximum leg press (1-RM; kg)c, using standard protocols18, 2)
Functional lower body strength by time to rise 5 times from a chair (sec)19 and 3) Functional
stair climb ability, a task that relies on muscular power, by time to ascend and time to
descend seven stairs (1.2 m) using standard protocols20 and described as stair climb speed
(m/s) and power (kg·m/s).
Muscle mass of the whole body was measured via DXAd. Participants lay supine on the
table and were positioned according to manufacturer guidelines for regional body
composition analysisd. Body composition was expressed as % whole-body lean mass and
leg lean mass (kg). In-house coefficients of variation for lean and fat mass in our laboratory
are <2.0%21.
Vision characteristics were assessed with a visual function battery consisting of the
following tests: Visual acuity using autorefractione; 2) Spatial contrast sensitivity (both eyes
aNeurocom Clinical Research System, NeuroCom International, Inc., 9570 SE Lawnfield Road, Clackamas, OR 97015 USA
bGAITrite electronic walkway system, CIR Systems, Inc., 60 Garlor Drive, Havertown, PA 19083
cVectra VX 38 multi-station weight machine, Vectra Fitness, 7901 South 190th Street, Kent, WA 98032 U.S.A
dHologic Discovery Wi densitometer, Hologic, Inc., 35 Crosby Drive, Bedford, MA 01730
eHumphrey Autorefractor/Keratometer Model 599, Carl Zeiss Meditec Inc., 5160 Hacienda Drive Dublin, CA 94568-7562
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together) using the Pelli-Robson chart at a luminance level of 40 cd/m2,f22. To assess task
difficulty, we recorded “Time to Hesitation” as the time from the start of the test at highest
contrast until subject first hesitated ≥ 5 seconds between successive letters at lower
contrasts; 3) Depth perception for near vision was assessed using the Randot® SO-002
Graded Circle Stereoacuity Testg; 4) Visual field sensitivity was measured using a white-on-
white central 30° screening testh.
Statistical analysis
Descriptive data for continuous variables are presented as means and standard deviations
and for categorical data as % of sample. Independent samples t-tests or chi-square were used
for comparisons on balance, neuromuscular, vision and treatment characteristics between
BCS with and without a history of falls. To explore predictors of falls over and above a
history of past falls, hierarchical logistic multiple regression was used to examine treatment,
balance, neuromuscular and vision variables that predicted fall status in the 6 month follow-
up period with variables that differed between groups at p<.15 considered for inclusion in
the logistic regression model as independent variables. Treatment was dummy coded to
examine the independent contributions of chemotherapy and adjuvant endocrine therapy to
fall prediction. To examine whether balance, neuromuscular and visual characteristics
mediate the relationship between treatment and falls we employed the product coefficients
approach to testing mediation23, 24, 25. Only variables significantly different between fallers
and non-fallers at baseline were explored as mediators.
RESULTS
Falls
Of the 143 women who expressed in the study, 59 women enrolled and all completed
baseline testing and six-month fall reports. On average, participants were 58 years old and
overweight (Table 1). Most women had Stage I-II breast cancer, were treated with
chemotherapy and were currently taking a SERM or an AI. At enrollment, 58% reported a
fall in the previous year and half of them experienced >1 fall (Table 2). Less than 10% of the
sample had a fracture after their cancer diagnosis, but most reported fractures were
associated with a fall. 53% of our sample experienced one or more falls during the six-
month follow up period. One-third of women with a previous fall history also fell in the 6-
month follow up period. Taking both observation periods into account, 76% of BCS in this
study reported falling after their cancer diagnosis within the 18-month time frame.
Differences between past fallers and non-fallers
Past fallers and non-fallers were of similar age and clinical status regarding breast cancer
history (Table 3 & 4). Past fallers had lower scores on condition 5 of the SOT (p<.01) (Fig
1) which contributed to differences on the VEST score (p<.01) (Table 4). Subjects who took
longer time to read letters on the contrast sensitivity chart were more likely to have a history
of falls (p<.05; Table 5). There were no other significant differences on the SOT, the muscle
function tests or the visual tests by fall history.
Predictors of future falls
After adjusting for fall history, the following variables were added in the regression model:
VEST score, VIS score, whole body % lean mass, stair descent speed, time to hesitation, and
fPelli-Robson chart, Lombart Instrument, 5358 Robin Hood Road, Norfolk, Virginia 23513
gStereo Optical Co. Inc. 8623 W. Bryn Mawr Ave., Suite 502 Chicago, IL 60631
hHumphrey Field Analyzer II model 750i, Carl Zeiss Meditec Inc., 5160 Hacienda Drive, Dublin, CA 94568-7562
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treatment type. Though stair ascent speed met our criterion for entry in the model (p<.15) it
was not included in the regression because of its large correlation with stair descent speed
and concern for multicollinearity. Time to (visual) hesitation and stair descent speed
introduced instability in the estimates of the standard errors so the model was rerun without
these variables. The final logistic regression model was not significant, χ2 (6) = 3.85, p >.
05; Table 6.
Mediators of the relationship between treatment and falls
VEST score was the only variable that met criteria for mediator models. Separate models
were run to examine whether VEST score mediated the relationship between past or future
falls and a particular treatment category (adjuvant endocrine therapy, chemotherapy, or
adjuvant endocrine therapy + chemotherapy). Treatment type had an indirect relationship
with past falls due to balance problems when relying on the vestibular system (Table 7). The
chemotherapy only group was 1.96 times more likely to have a history of falls than the
group that received chemotherapy + endocrine therapy via the effect of treatment on VEST
score (95% bias-corrected and accelerated CI for the odds ratio: 1.05 – 6.38). VEST score
did not mediate the relationship between treatment type and future falls.
DISCUSSION
Our study is the first to consider how breast cancer treatment may increase fall risk by using
a comprehensive set of objective measures of fall risk and by exploring mediators of the
treatment-falls relationship. Our findings suggest that recently treated postmenopausal BCS
have higher rates of falling compared to population averages for community-dwelling older
adults and that balance disturbances may explain how treatment could increase falls in BCS.
Difficulties responding quickly to low spatial contrasts may also contribute to falls in this
population, in which vision disturbances associated with adjuvant endocrine therapy have
been reported11–15. By aggregating fall history data and prospective fall data, 76% of BCS
fell within an 18-month period. Alterations in vestibular inputs to balance control may
explain the relationship between breast cancer treatment and falls observed in women whose
systemic treatment was cytotoxic chemotherapy alone.
Among our sample of postmenopausal BCS, the incidence of falls is nearly double the 25%–
30% annual fall rate reported for community-dwelling older adults over 65 years of age26. In
our study, 58% of BCS experienced a fall in the year prior to enrollment and nearly half
(47%) fell within six-months thereafter. Our results agree with those reported by Chen et al
(2005) that BCS have a 15% higher risk of falls than non-BCS3. In contrast, studies in older
cancer survivors report similar fall histories between older adults receiving treatment for
cancer and cancer-free older adults 27, 28. Age and treatment differences may explain the
discrepancies between falls data in BCS studies versus studies of older adults with mixed
cancer diagnoses. At least in BCS, higher fall risk should be considered as a potential
consequence of treatment. In turn, falls may lead to injury, activity limitations due to fear of
falling29, and eventually contribute to functional decline30.
We measured a comprehensive set of neuromuscular and balance characteristics known to
be associated with falls but only balance discriminated fallers from non-fallers. BCS who
fell had significantly lower scores on condition 5 of the SOT, indicating a vestibular-related
deficit in balance control. Using similar methods, Wampler (2007) reported lower scores on
five of six SOT tests, and particularly lower vestibular scores among BCS treated with
taxane therapy compared to healthy, age-matched controls31. SOT scores from our BCS
group are similar to those of Wampler’s BCS sample, but vestibular scores among the fallers
in our study are even lower and sway in other conditions was not abnormal. The similar
SOT results for vestibular scores reported for both studies may reflect a consistent side
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effect of breast cancer treatment, particularly chemotherapy. Doxobubicin (adriamycin),
used in most combination chemotherapy for breast cancer, is an aminoglycoside. This class
of drugs is associated with vestibular ototoxicity32. Ototoxic side effects from chemotherapy
drugs for breast cancer have received very little attention in the literature. Of the two studies
including BCS, aminoglycosides were linked to ototoxicity in BCS only33, while ototoxicy
from taxanes was not observed in breast plus ovarian cancer survivors7. Ototoxicity results
in loss of hair cells in the vestibular system even before noticeable hair cell loss in the
cochlea for hearing and consistently results in abnormal scores in SOT conditions 5 and 6,
despite normal sway in conditions 1–434. Together, our study and Wampler’s suggest that
breast cancer treatment may adversely affect the vestibular inputs to balance control and this
may lead to falls. However, since past, but not future falls could be predicted by balance
problems, it is possible that vestibular or other deficits impairing balance function were most
severe during and immediately following chemotherapy and lessen over time or are
compensated for by increased reliance on other sensory systems to maintain balance35.
Wampler et al (2007) also reported that BCS treated with taxane-based chemotherapy had
worse visual acuity at low but not high-contrast, as compared with healthy control subjects.
In our study the average contrast sensitivity level itself was not significantly different
between fallers and non-fallers which could be because the Pelli-Robson test assesses
contrast sensitivity far above the visual acuity limit. In addition, we found the relation of
falls to contrast sensitivity to depend on the time taken by subjects to respond correctly. In
the absence of time constraints, subjects may view the low-contrast letters for upwards of
ten seconds before identifying the correct letters. A decision period this long would be of
little help to a person navigating real-world environments where falls occur. Our results may
help explain discrepancies in the literature on the relation of contrast sensitivity to falls36–38.
In the mediator models, chemotherapy treatment had an indirect effect on falls through its
effect on vestibular balance scores when contrasted with the group that received
chemotherapy + adjuvant endocrine therapy where no relationship with vestibular balance
scores and falls existed. However, there was no indirect effect found for adjuvant endocrine
therapy only and falls via vestibular scores when compared to those who received
chemotherapy + adjuvant endocrine therapy. The differences between treatment groups may
be confounded by different health and disease status of the patient that dictated type of
treatment. Women who do not receive adjuvant endocrine therapy for breast cancer are more
likely to have hormone receptor negative disease that is not responsive to SERMs or AIs39.
These BCS may be more likely to receive high-dose chemotherapy40 and/or anthracycline-
based chemotherapy41 thus, may be more vulnerable to side effects of this type of
chemotherapy treatment. Given the variation in dose and type of chemotherapy and the
impact of these variations on the nature and magnitude of treatment-related side effects, it
will be important for future studies to obtain complete treatment information on participants
and/or focus on specific chemotherapeutic agents.
Study Limitations
Our study has limitations. The analyses using retrospective falls data are cross-sectional and
cannot establish cause and effect; in fact, we only counted falls that occurred in the past year
and after cancer diagnosis to retain the plausible link to cancer treatment. Due to challenges
inherent to abstracting medical records from diverse hospital systems among our community
sample, we were unable to obtain full information on chemotherapy drugs and doses
received by participants so we cannot link specific chemotherapy agents to falls. We did not
include measures of peripheral neuropathy, a common side effect of chemotherapy
associated with falls; however, the SOT somatosensory scores were similar between fallers
and non-fallers (Fig 1) suggesting that peripheral neuropathy may not underlie balance
problems in this sample. Our study may have attracted women concerned about falling and
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results may not generalize to the broader population of BCS. Our sample size was relatively
small but appropriate for preliminary work and intended to inform future studies.
CONCLUSIONS
Falls in BCS are understudied and deserve more attention, particularly in light of the
increase in fractures after breast cancer treatment and the relationship of falls to fractures.
Our findings add to growing evidence that fall risk is increased in BCS and that vestibular
function may underpin associations between breast cancer treatment and falls. Our results
also suggest that standard contrast sensitivity tests may not capture delays in contrast
detection that might contribute to falls. Collectively, knowledge from this study will inform
future studies of falls in cancer survivors as well as contribute to the development of specific
interventions that target BCS at risk of falling. To date, only strength training has been
examined for effects on falls in BCS42. This study did not specifically target BCS who fell
and exercise did not reduce falls. Given our findings suggesting that strength is not a
predictor of falls in BCS, strength training less effective in BCS than in older adults where
strength is a predictor of falls. Future studies may consider a multi-factorial interventions for
reducing falls that include vestibular rehabilitation techniques and environmental
modifications to enhance contrast.
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List of abbreviations
BCS breast cancer survivor
SOT sensory organization test
CNS central nervous system
CDP computerized dynamic posturography
SOM somatosensory
VEST vestibular
VIS vision
PREF preference
1-RM one-repetition maximum
m/s meters per second
kg·m/s kilogram-meters per second
DXA dual energy x-ray absorptiometry
cd/m2 candela per square meter
SERM selective estrogen receptor modulator
AI aromatase inhibitor
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Fig. 1.
Comparison of equilibrium scores by condition on the baseline Sensory Organization Test
between BCS with a positive or negative fall history. Figure illustrating the sensory system
alterations are placed below each condition number.
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Table 1
Health history of breast cancer survivors (N=59)
Treatment Mean (SD) or % of Sample
Age 58.5 (9.7)
BMI (kg/m2) 28.3 (7.2)
Months since diagnosis 20.9 (6.5)
Stage 0 5%
Stage I 29%
Stage II 39%
Stage III 19%
Chemotherapy only (N=17) 29%
Current adjuvant endocrine therapy (N=19)
 SERM use only (N=7) 12%
 Current AI use only (N=12) 20%
Chemotherapy + current SERM or AI use (N=23) 39%
Abbreviations: SERM: Selective estrogen receptor modulator; AI: Aromatase inhibitor
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Table 2
Proportion of falls and fractures reported by breast cancer survivors (N=59) in the past year* and over the 6-
month observation period
% of Sample
At least one fall in past year 58%
Multiple falls in past year 31%
Recent fracture 8%
Recent fracture related to fall 5%
At least one fall occurring over 6 month observation period 53%
Multiple falls occurring over 6 month observation period 14%
At least one fall in past year or over 6 month observation period 76%
*
fall or fracture must have occurred within the year prior to enrollment and after cancer diagnosis.
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Table 3
Comparison of participants with positive and negative fall history* on demographic and clinical information
(mean (SD) or % of group) collected at enrollment. Percentages reflect the proportion of the sample
possessing a clinical characteristic within each fall group.
Positive fall history (N=34) Negative fall history (N=25) p-value
Age (yrs) 59.2 (7.1) 57.4 (12.4) 0.52
Time since diagnosis (mos.) 22.3 (5.8) 19.0 (7.1) 0.41
Breast cancer stage 0.19
  Stage 0 9% 0% --
  Stage I 27% 37% --
  Stage II 49% 32% --
  Stage III 15% 31% --
Treatment
 Chemotherapy only 29% 28% 0.46
 Current SERM use only 15% 4% 0.28
 Current AI use only 15% 24% 0.16
 Chemotherapy + SERM or AI use 41% 44% 0.72
*
Number of falls reported over 12 months prior to baseline testing
Abbreviations: SERM = selective estrogen receptor modulator; AI = aromatase inhibitor
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Table 4
Comparison of participants with positive and negative fall history* on baseline neuromuscular and balance
characteristics (mean (SD) or % of group)
Positive fall history (n=34) Negative fall history (N=25) p-value
BMI (kg/m2) 29.3 (8.3) 26.9 (5.1) 0.22
Whole body % lean mass 60.7 (6.8) 63.4 (6.2) 0.12
Leg lean mass (kg) 15.0 (3.3) 14.4 (2.4) 0.46
Maximal leg press (kg) 86.0 (30.4) 78.6 (19.5) 0.30
Chair stand time (sec to complete 5 stands) 12.6 (3.0) 11.8 (3.3) 0.31
Stair climb power (kg·m/sec) 28.3 (6.7) 28.2 (7.0) 0.96
Stair ascent speed (m/sec) .25 (.04) .27 (.05) 0.09
Stair descent speed (m/sec) .28 (.07)* .31 (.05) 0.07
Best fast walk (m/sec) .43 (.07) .48 (.07) 0.21
Average usual walk (m/sec) .30 (.05) .33 (.05) 0.21
SOT-somatosensory 94.6 (7.2) 95.6 (3.5) 0.52
SOT-visual 77.6 (19.1) 84.1 (8.5) 0.12
SOT-vestibular 41.4 (25.0) 57.3 (18.7) 0.01
SOT-preference 96.6 (23.6) 98.6 (11.5) 0.70
*
Number of falls reported over 12 months prior to baseline testing
Abbreviations: SOT: Sensory organization test
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Table 5
Comparison of participants with positive and negative fall history* on baseline vision characteristics (mean
(SD) or % of group)
Positive fall history (N=34) Negative fall history (N=25) p-value
Visual acuity – right eye† 0.9 (0.2) 0.9 (0.3) 0.63
Visual acuity – left eye† 0.6 (0.7) 0.6 (0.5) 0.89
Contrast sensitivity‡ 1.8 (0.2) 1.8 (0.2) 0.73
Contrast sensitivity time to hesitation (sec)§ 29.0 (10.5) 24.6 (6.1) 0.04
Contrast sensitivity at hesitation§ 1.7 (0.1) 1.7 (0.1) 0.99
Stereovision (arcsec)|| 88.5 (169.0) 173 (314.7) 0.63
Visual field sensitivity (# of missed points)¶ 0.8 (2.6) 3.8 (8.5) 0.10
*
Number of falls reported over 12 months prior to baseline testing;
†
Scores < 1 indicate poorer than 20/20 acuity;
‡
higher scores indicate better contrast sensitivity;
§
higher scores indicate more delay in detecting letters at low contrast; sample sizes for contrast sensitivity were positive fall history: N=31 and
negative fall history: N=23 and for contrast sensitivity hesitation time and line were N=29 and N=22 due to missing data;
||
lower scores (arcsec) indicate better stereovision;
¶
higher scores imply poorer coverage of the visual field
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Table 6
Logistic regression results for prediction of faller status over six-month observation period (odds ratio + 95%
confidence interval). Independent variables were assessed at baseline.
Independent Variable Odds Ratio p-value
History of falls in previous year 0.86 (0.27, 2.69) 0.79
Whole body percent lean mass 1.00 (0.92, 1.01) 0.94
SOT-vision 0.97 (0.93, 1.01) 0.17
SOT-vestibular 0.99 (0.97, 1.03) 0.77
Adjuvant endocrine therapy only* 1.42 (0.41, 4.90) 0.58
Chemotherapy only† 1.32 (0.31, 5.64) 0.71
*
Comparison of participants who only had adjuvant endocrine therapy to participants who had chemotherapy + adjuvant endocrine therapy;
†
Comparison of participants who had chemotherapy only compared to participants who had chemotherapy + adjuvant endocrine therapy
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